Search clinical trials for: AZD5438

Total 73 results

AstraZeneca

Completed

AZD5438 in Patients With Advanced Solid Malignancies

Neoplasms

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers

Coronary Artery Disease (CAD)

United Kingdom
AstraZeneca
Parexel

Completed

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

Chronic Kidney Disease

United Kingdom
AstraZeneca

Active, not recruiting

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Advanced Solid Tumours

United States, France, Spain
AstraZeneca

Completed

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

Type 2 Diabetes

United States
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
Massachusetts General Hospital
AstraZeneca

Recruiting

AZD6738 for Patients With Progressive MDS or CMML

Leukemia | Myelodysplastic Syndrome

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers

Coronary Artery Disease

United Kingdom
Royal Marsden NHS Foundation Trust
AstraZeneca; Cancer Research UK; RM/ICR Biomedical Research Centre

Active, not recruiting

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

Solid Tumour Refractory to Conventional Treatment

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Terminated

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

Healthy

United States
National University Heart Centre, Singapore
AstraZeneca

Recruiting

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE (PASSIVATE)

Acute Coronary Syndrome

Australia, New Zealand, Singapore
Oxford University Hospitals NHS Trust
University of Oxford; Cancer Research UK; National Institute for Health Research...

Completed

Phase 1 Trial of CXD101 in Patients With Advanced Cancer

Advanced Cancer

United Kingdom
AstraZeneca

Completed

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). (FLAVOUR)

Coronary Artery Disease

Denmark, Finland, Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

Pulmonary/Respiratory Diseases

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

Cystic Fibrosis

United States
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca
Parexel

Completed

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Completed

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Bioavailability and AUC

United Kingdom
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Recruiting

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

Ovarian Cancer | Lung Adenocarcinoma

Spain, China, United States, Australia, Taiwan, Canada, Israel, Japan, United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
AstraZeneca

Completed

AZD5423 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects

Healthy

Japan
AstraZeneca

Not yet recruiting

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA)

Chronic Heart Failure
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Se-Hoon Lee
AstraZeneca

Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (SUKSES-N4)

Small Cell Lung Cancer

Korea, Republic of
University of Nottingham

Completed

Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.

Insulin Resistance | Age Problems

United Kingdom
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
Mette M Berger
Texas A&M University

Completed

Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients? (HMB-ICU-CH)

Critical Illness | Muscle Weakness

Switzerland
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of
AstraZeneca

Completed

A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Healthy | Asthma

United Kingdom
AstraZeneca

Completed

A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet

High Risk Coronary Artery Disease

United Kingdom
Daiichi Sankyo

Available

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

United States
Samsung Medical Center

Completed

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

SCLC

Korea, Republic of
University of Pennsylvania
AstraZeneca; Myriad Genetics, Inc.

Recruiting

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)

High Grade Serous Carcinoma

United States
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
University of Michigan Rogel Cancer Center

Active, not recruiting

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Prostate Cancer

United States
Samsung Medical Center

Completed

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Refractory Cancer

Korea, Republic of
Institute of Cancer Research, United Kingdom
AstraZeneca; Cancer Research UK

Recruiting

ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)

Gynaecological Cancers

United Kingdom
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
AstraZeneca
Parexel; George Clinical Pty Ltd

Terminated

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Chronic Kidney Disease

United States, Taiwan, Germany, Hungary, Malaysia, Japan, Israel, Poland, Brazil, Ukraine, Argentina
Dana-Farber Cancer Institute
AstraZeneca; Osteosarcoma Institute

Recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Osteosarcoma | Osteosarcoma Recurrent

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Medical Center

Completed

Sodium Stibogluconate Treatment of Leishmaniasis

Leishmaniasis

United States
Tribhuvan University, Nepal

Completed

Does Antibiotics Use During Surgery Help to Decrease Wound Infection and Increase Success After Ear Surgery in Children

Post Operative Wound Infection | Graft Uptake | Myringoplasty
Seoul National University Hospital

Active, not recruiting

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Joseph Paul Eder
Dana-Farber Cancer Institute; The Cleveland Clinic; Vanderbilt-Ingram Cancer...

Terminated

OLAParib COmbinations (OLAPCO)

Cancer

United States

3

Subscribe